CardioGenesis Prepares For New Trial Of Percutaneous Laser Angina Device
This article was originally published in The Gray Sheet
Executive Summary
CardioGenesis credits the recent regulatory progress of its Axcis laser percutaneous myocardial channeling (PMC) system to the contributions of Syncardia CEO Marvin Slepian, MD
You may also be interested in...
Percutaneous Myocardial Laser Developer Drafts IDE Agreement With FDA
CardioGenesis will meet with FDA by year-end to finalize a clinical trial protocol to support PMA approval of its Axcis laser percutaneous myocardial channeling (PMC) system for treating severe angina
Percutaneous Myocardial Laser Developer Drafts IDE Agreement With FDA
CardioGenesis will meet with FDA by year-end to finalize a clinical trial protocol to support PMA approval of its Axcis laser percutaneous myocardial channeling (PMC) system for treating severe angina
SynCardia Artificial Heart Safety Should Be Confirmed Postmarket – Panel
A postmarket study of SynCardia's CardioWest Total Artificial Heart (TAH) is needed to confirm that its safety remains in the same range as shown in the firm's non-randomized PMA study, according to FDA's Circulatory System Devices Panel